Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9224
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHo, Y Ven
dc.contributor.authorFrauman, Albert Gen
dc.contributor.authorThomson, Wen
dc.contributor.authorSeeman, Egoen
dc.date.accessioned2015-05-15T22:14:05Z
dc.date.available2015-05-15T22:14:05Z
dc.date.issued2000en
dc.identifier.citationOsteoporosis International : A Journal Established As Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of The Usa; 11(2): 98-101en
dc.identifier.govdoc10793867en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9224en
dc.description.abstractAlendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis. As there are no proven safe and effective treatments available for men with osteoporosis, we compared the effects of alendronate (10 mg/day) on BMD, measured using dual-energy X-ray absorptiometry, in a 12-month prospective, controlled, open label study involving (i) men with primary (n = 23) or secondary osteoporosis (n = 18), (ii) postmenopausal women with primary (n = 18) or secondary (n = 21) osteoporosis, and (iii) 29 male and 14 female untreated controls matched by age, height and weight. The patients had one or more vertebral fractures and ranged in age from 34.6 to 85.1 years. BMD was detectably increased relative to baseline by 6 months, and increased by comparable amounts in males and females with primary or secondary osteoporosis. At 12 months, lumbar spine BMD was 5.4% +/- 1.1% to 7.0% +/- 2.2% higher in the treated groups compared with baseline and controls (p < 0.05 to 0.0001). Trochanteric BMD increased by 2.6% +/- 1.5% and 3.7% +/- 1.7% in treated men with primary and secondary osteoporosis, respectively (p = 0.06 to 0.08), and by 3.9% +/- 1.3% in treated women with primary osteoporosis (p < 0.01) after 12 months. No significant changes were detected at the femoral neck or Ward's triangle. BMD remained unchanged in controls. We infer that alendronate has comparable incremental effects on BMD in men and women with primary and secondary osteoporosis within 12 months of treatment. The changes are in the order of 0.5 SD--effects associated with a clinically worthwhile reduction in fracture risk. The data provide room for optimism regarding the role of alendronate in the treatment of osteoporosis in men. Randomized, double-masked and placebo-controlled trials are needed to confirm these preliminary findings and demonstrate antifracture efficacy using vertebral and nonvertebral fracture rates as the primary endpoint.en
dc.language.isoenen
dc.subject.otherAbsorptiometry, Photonen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAlendronate.therapeutic useen
dc.subject.otherAntimetabolites.therapeutic useen
dc.subject.otherBone Density.drug effectsen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOsteoporosis.drug therapyen
dc.subject.otherOsteoporosis, Postmenopausal.drug therapyen
dc.titleEffects of alendronate on bone density in men with primary and secondary osteoporosis.en
dc.typeJournal Articleen
dc.identifier.journaltitleOsteoporosis Internationalen
dc.identifier.affiliationDepartment of Endocrinology, Austin and Repatriation Medical Centre, University of Melbourne, Heidelberg, Victoria, Australia.en
dc.identifier.doi10.1007/PL00004182en
dc.description.pages98-101en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/10793867en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.